AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Vitamin K2 Supplementation in Adult Episodic Migraine

RecruitingNAAges 18 Years - anyAllSola Aoun Bahous, M.D. Ph.D.
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 years or above * History of episodic migraine with or without aura since \> 12 months according to the ICHD-3 criteria. * Migraine frequency from 4-14 days per month over the 3 months prior to screening. * Migraine frequency from 4-14 days per month during the baseline period of assessment. * Successful completion of the migraine diary during the baseline evaluation period. Exclusion Criteria: * Migraine patients with superimposed tension type or other forms of primary headaches * Patients who are currently on any of the migraine prophylactic treatments (Sodium valproate, Topiramate, Beta-blockers, Tricyclic antidepressants, SRNI, Flunarizine, Verapamil, Lisinopril, Candesartan) * Patients who have been on any of the previously listed medications within 3 months of screening * Patient who takes the following medications: * Ergotamine or Triptans \> 10 days per month * NSAIDs or paracetamol \> 15 days per month * Opioids more than 4 days per month * Patients on anticoagulants * Other active chronic pain syndromes (i.e. fibromyalgia, painful peripheral neuropathy, post-herpetic neuralgiaโ€ฆ) * History of hypersensitivity to the vitamin K2 * History of soy protein, cheese, eggs and meat allergy * History of thrombotic events * Diagnosed coagulopathy or any condition related to coagulation * Cardiovascular event in the past month * Current or planned pregnancy * Lactation * Inability to tolerate oral medications * Known intestinal malabsorption or hypomotility syndromes * Atrial fibrillation * Active malignancy * Any acute illness in the past month
๐Ÿ’Š

What it tests

  • Vitamin K2 or menaquinone-7
  • Placebo
๐Ÿ“

Where

1 site
Lebanese American University Medical Center - Rizk Hospital
Beirut, Lebanon
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy